Virtus ETF Advisers LLC Cassava Sciences Inc Transaction History

Virtus ETF Advisers LLC

$206 Million
Q3 2024

A detailed history of Virtus ETF Advisers LLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 4,634 shares of SAVA stock, worth $11,816. This represents 0.07% of its overall portfolio holdings.

Number of Shares

4,634

Previous 4,551 1.82%

Holding current value

$11,816

Previous $56,000 142.86%

% of portfolio

0.07%

Previous 0.03%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$9.57 - $35.08 $794 - $2,911	83 Added 1.82%	4,634 $136,000
Q2 2024 Aug 14, 2024	BUY	$12.35 - $26.11 $20,649 - $43,655	1,672 Added 58.08%	4,551 $56,000
Q1 2024 May 15, 2024	SELL	$18.44 - $26.41 $3,614 - $5,176	-196 Reduced 6.37%	2,879 $58,000
Q4 2023 Feb 15, 2024	SELL	$12.64 - $30.11 $10,516 - $25,051	-832 Reduced 21.3%	3,075 $69,000
Q3 2023 Nov 07, 2023	SELL	$16.64 - $25.32 $6,423 - $9,773	-386 Reduced 8.99%	3,907 $65,000
Q2 2023 Aug 14, 2023	BUY	$21.59 - $27.88 $43,287 - $55,899	2,005 Added 87.63%	4,293 $105,000
Q1 2023 May 15, 2023	SELL	$23.46 - $36.44 $20,809 - $32,322	-887 Reduced 27.94%	2,288 $55,000
Q4 2022 Feb 14, 2023	SELL	$27.82 - $44.16 $30,379 - $48,222	-1,092 Reduced 25.59%	3,175 $93,000
Q3 2022 Nov 14, 2022	BUY	$16.33 - $51.06 $424 - $1,327	26 Added 0.61%	4,267 $178,000
Q2 2022 Aug 12, 2022	BUY	$17.22 - $38.47 $16,221 - $36,238	942 Added 28.55%	4,241 $119,000
Q1 2022 May 16, 2022	SELL	$32.6 - $53.05 $6,520 - $10,610	-200 Reduced 5.72%	3,299 $123,000
Q4 2021 Feb 14, 2022	BUY	$36.77 - $90.91 $25,775 - $63,727	701 Added 25.05%	3,499 $153,000
Q3 2021 Nov 15, 2021	SELL	$41.79 - $135.3 $6,393 - $20,700	-153 Reduced 5.18%	2,798 $174,000
Q2 2021 Aug 10, 2021	BUY	$32.15 - $89.72 $94,874 - $264,763	2,951 New	2,951 $252,000

Others Institutions Holding SAVA

# of Institutions

207

Shares Held

14M

Call Options Held

2.98M

Put Options Held

6.57M

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $102M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.

Account

Virtus ETF Advisers LLC Cassava Sciences Inc Transaction History